Comparison Chart Acurx Pharmaceuticals, Inc.
Stocks
ACXP
US00510M2035
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.580 USD | -1.25% |
|
-10.73% | -36.55% |
| 05-20 | Acurx Pharmaceuticals Highlights FDA's Guidance That Could Accelerate Approval Path for Ibezapolstat | CI |
| 05-12 | Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ACURX PHARMACEUTICALS, INC. | Other Biotechnology & Medical Research | -1.25% | -10.73% | -36.55% | -77.43% | - | 6.85M |  |  | |
- Stock Market
- Stocks
- ACXP Stock
- Charts Acurx Pharmaceuticals, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
